Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
Diabetes Obes MetabJul 6, 2026 (epub)
Unnikrishnan Ambika Gopalakrishnan, Ameya Joshi, Harish Kumar et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized Phase III trial evaluated the efficacy and safety of Test semaglutide versus Reference semaglutide for weight management in 270 adults with obesity or overweight. At Week 24, the mean percent weight change was -13.8% for Test and -14.1% for Reference, demonstrating non-inferiority with a least-squares mean difference of 0.26%.
Key findings
- Mean percent weight change at Week 24 was -13.8% for Test semaglutide and -14.1% for Reference semaglutide.
- 96.40% of Test group patients achieved ≥5% weight loss compared to 98.80% in the Reference group.
- Treatment-emergent adverse events occurred in 72.30% of Test and 76.70% of Reference group patients.
Why it matters
The findings support the use of Test semaglutide as an effective alternative for weight management in adults with obesity, potentially expanding treatment options for clinicians managing this population.